Drugs / FPV-gp100
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00019175 | Aug 1996 → ? | cutaneous melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FPV-gp100 | “Patients receive recombinant fowlpox virus encoding the gp100 melanoma antigen (FPV-gp100) IV or intramuscularly to rotating sites” NCT00019175 ↗ |
| Modality | Vaccine | “immunization with a recombinant fowlpox virus encoding the gp100 melanoma antigen” NCT00019175 ↗ |
| Route | Intramuscular | “FPV-gp100) IV or intramuscularly to rotating sites” NCT00019175 ↗ |
| Route | Intravenous | “FPV-gp100) IV or intramuscularly to rotating sites” NCT00019175 ↗ |